The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma

Oncotarget

Volumn 6, Issue 31, 2015, Pages 31593-31603

  Stronach, Euan A ^a   Cunnea, Paula ^a   Turner, Christina ^b   Guney, Tankut ^b   Aiyappa, Radhika ^c   Jeyapalan, Senthuran ^b   de Sousa, Camila H ^a   Browne, Alacoque ^b   Magdy, Nesreen ^b,d   Studd, James B ^a   Sriraksa, Ruethairat ^e   Gabra, Hani ^a   El Bahrawy, Mona ^b,f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^d CAIRO UNIVERSITY   (Egypt)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Carcinoma; Chemoresistance; Cytokine; Interleukin 8; Ovary

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BIOLOGICAL MARKER; CISPLATIN; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; BAD PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; IL8 PROTEIN, HUMAN; PROTEIN BAD;

APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CARCINOMA CELL LINE; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; GENE EXPRESSION; GENE LOCATION; GENE SILENCING; HUMAN; HUMAN CELL; IC50; IL 8 GENE; IN VITRO STUDY; ONCOGENE; OVARY CARCINOMA; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-8; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84945144878     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3415     Document Type: Article

References (32)

1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3:502-516.
2. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011; 377:127-138.
3. McGuire WP. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Oncol. 2009; 27:4633-4634.
4. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecologic oncology. 2009; 112:275-281.
5. Marcu L, Bezak E, Olver I, van Doorn T. Tumour resistance to cisplatin: a modelling approach. Physics in medicine and biology. 2005; 50:93-102.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews Cancer. 2007; 7:573-584.
7. Balkwill F. Cancer and the chemokine network. Nature reviews Cancer. 2004; 4:540-550.
8. Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm. 2009; 24:369-376.
9. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001; 12:375-391.
10. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer research. 2007; 67:6854-6862.
11. Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G, Del Bufalo D. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. European journal of cancer. 2009; 45:2618-2627.
12. Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003; 18:1681-1685.
13. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012; 59:145-155.
14. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D, Khalifa A. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004; 37:363-369.
15. Mayerhofer K, Bodner K, Bodner-Adler B, Schindl M, Kaider A, Hefler L, Zeillinger R, Leodolter S, Joura EA, Kainz C. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer. 2001; 91:388-393.
16. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008; 100:359-372.
17. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL-and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther. 2008; 7:2649-2661.
18. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999; 5:3445-3453.
19. Lee LF, Haskill JS, Mukaida N, Matsushima K, Ting JP. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Molecular and cellular biology. 1997; 17:5097-5105.
20. Lee LF, Schuerer-Maly CC, Lofquist AK, van HaaftenDay C, Ting JP, White CM, Martin BK, Haskill JS. Taxoldependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res. 1996; 56:1303-1308.
21. Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E, Gabra H, Stronach E, El-Bahrawy M. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine. 2013; 64:413-421.
22. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Human pathology. 2009; 40:1213-1223.
23. Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine. 2011; 56:365-375.
24. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 2007; 56:25-33.
25. Singh S, Wu S, Varney M, Singh AP, Singh RK. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res. 2011; 82:318-325.
26. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011; 71:4412-4422.
27. Aggarwal SK. A histochemical approach to the mechanism of action of cisplatin and its analogues. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 1993; 41:1053-1073.
28. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:6735-6741.
29. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC, Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer research. 1988; 48:6166-6172.
30. Chao J, Taveras AG, Chao J, Aki C, Dwyer M, Yu Y, Purakkattle B, Rindgen D, Jakway J, Hipkin W, Fosetta J, Fan X, Lundell D, Fine J, Minnicozzi M, Phillips J, et al. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorganic & medicinal chemistry letters. 2007; 17:3778-3783.
31. Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, Lundell D, Fine JS, Grant EP. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochemical and biophysical research communications. 2010; 391:1080-1086.
32. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2011; 13:1069-1080.